Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rimexolone · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Rimexolone | DRUG | - |
Inclusion Criteria: * documented dry eye history * ocular symptoms * tear use * dry eye ocular signs Exclusion Criteria: * Under 18
Rimexolone is a small molecule being developed by Alcon Inc. for the treatment of Dry Eye. It is currently in Phase 3 clinical development, though the single completed trial was actually a Phase II study. The drug is administered to patients with Dry Eye, a condition affecting the ocular surface.
Rimexolone is being developed by Alcon Inc., a company traded under the ticker symbol ALC. Alcon is focused on ophthalmology products, and Rimexolone is one of its investigational assets for Dry Eye. The drug is a small molecule, and it has completed one clinical trial.
Rimexolone is in Phase 3 clinical development for Dry Eye. However, the only trial listed for this drug is a completed Phase II study with 750 participants. This trial was randomized and double-blind, but it did not use a control group, meaning it was uncontrolled.
Rimexolone has one completed clinical trial, identified as NCT00471419, titled 'Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye.' This trial enrolled 750 participants in the United States, with a minimum age of 18 years, and included both sexes. The study was randomized and double-blind, but uncontrolled.
Yes, Rimexolone is the same as AL-2178, as indicated by the clinical trial title. The trial NCT00471419 refers to the drug as AL-2178 (FID 109980). This alternative name is used in the context of the Phase II study for Dry Eye, and it is being developed by Alcon Inc.